Mitotane
Mitotane is an anticancer chemotherapeutic compound clinically used to treat adrenocortical carcinoma, as it targets only adrenal cells and not others. In adrenocortical cells, mitotane inhibits secretion of cortisol and 17-hydroxyprogesterone and decreases activity of cytochrome c oxidase, suppressing mitochondrial respiration and inhibiting cell proliferation. Mitotane may induce hyperlipidemia in clinical subjects, as it increases serum levels of LDL, HDL, and triglycerides.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18945216
| Cas No. |
53-19-0 |
|---|---|
| Purity |
≥98% |
| Formula |
C14H10Cl4 |
| Formula Wt. |
320.04 |
| IUPAC Name |
1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene |
| Melting Point |
76-78C |
| Appearance |
White to off white powder |
Shawa H, Deniz F, Bazerbashi H, et al. Mitotane-induced hyperlipidemia: a retrospective cohort study. Int J Endocrinol. 2013;2013:624962. PMID: 24348556.
Hescot S, Slama A, Lombès A, et al. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer. 2013 May 21;20(3):371-81. PMID: 23696597.
Fang VS. Cytotoxic activity of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (mitotane) and its analogs on feminizing adrenal neoplastic cells in culture. Cancer Res. 1979 Jan;39(1):139-45. PMID: 761184.
